Johnson & Johnson CEO: We Made a Mistake
J&J CEO William Weldon was summoned to testify before the US House Committee on Oversight and Government Reform Thursday. In his testimony, he admitted the pharmaceutical company made mistakes...
FDA & Prescription Drugs
Related Articles
Bone Drugs May Increase Esophageal Cancer Risk
Drugs such as Actonel, Boniva, and Fosamax may increase the risk of contracting esophageal cancer, according to a new study published today in the British Medical Journal. The bone drugs belong to a...
Zicam Class Action Settlement Does Not Settle Loss of Smell Injury Cases
Today, Matrixx Initiatives, Inc., the manufacturer of Zicam Nasal Spray and Swabs cold remedies, announced that it had an agreement to settle lawsuits against the Company. However, the reported...
FDA Will Re-Assess Avandia
As Senate Finance Committee documents reveal that the FDA suggested GlaxoSmithKline recall its diabetes drug Avandia because of its association with heart attacks, there are more calls for the drug...
Federal Fines for Off-Label Marketing May Be Paying Dividends
Perhaps the large pharmaceutical companies are finally starting to pay attention. After a few years of being penalized by large monetary fines, it may be that the big pharma executives are starting...
FDA’s Oversight of Post-Marketing Studies Inadequate
The Government Accountability Office (GAO) has released a new report about the FDA’s lack of post-marketing oversight in a number of the drugs which it conditionally approved. The FDA...
The FDA Must Improve Communication to Patients
The American Recovery and Reinvestment Act allocated $1.1 billion dollars to coordinate research and guide investments in comparative research funded by the Act. Some critics suggest that a whole...
Injectable Pain Drug Recall Expanded
The manufacturer of an injectable pain medicine is expanding its recall due to possible contamination. The recalled drug Ketorolac Tromethamine Injection USP 30 mg/ml, is used to treat moderate to...
Pfizer Pleads Guilty to Criminally Illegal Marketing
Earlier this month, drug giant Pfizer agreed to pay a $2.3 billion penalty to settle claims over payment of kickbacks and illegal drug marketing and promotion that violated federal drug laws...
Free Drug Samples: Does it Really Benefit a Patient?
A problem we have come across time and again in our personal injury practice is that drug samples handed out by medical providers are often not well-documented (if even documented at all) in our...
